Rudolph Navari to Serotonin 5-HT3 Receptor Antagonists
This is a "connection" page, showing publications Rudolph Navari has written about Serotonin 5-HT3 Receptor Antagonists.
Connection Strength
3.283
-
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Apr 07; 374(14):1356-67.
Score: 0.558
-
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta. 2015 Oct; 1848(10 Pt B):2738-46.
Score: 0.520
-
Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014 Dec; 15(17):2599-608.
Score: 0.504
-
Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opin Drug Metab Toxicol. 2009 Dec; 5(12):1577-86.
Score: 0.359
-
Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw. 2007 Jan; 5(1):51-9.
Score: 0.293
-
Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol. 2006 Oct; 2(5):591-602.
Score: 0.288
-
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer. 2018 Aug; 26(8):2519-2549.
Score: 0.162
-
Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. Paediatr Drugs. 2017 Jun; 19(3):213-222.
Score: 0.151
-
Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents. Drugs. 2013 Mar; 73(3):249-62.
Score: 0.112
-
New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct; 12(5):341-7.
Score: 0.072
-
Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar; 11(1):137-51.
Score: 0.069
-
Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials. Cancer Invest. 2004; 22(4):569-76.
Score: 0.060
-
Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. J Support Oncol. 2003 Jul-Aug; 1(2):89-103.
Score: 0.058
-
Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. Crit Rev Oncol Hematol. 2019 Oct; 142:164-186.
Score: 0.044
-
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016 Apr; 57:23-30.
Score: 0.034